No Data
C-Suite Buy of the Week: Unusual Insider Trading Trends as 2025 Approaches
Several Insiders Invested In Avadel Pharmaceuticals Flagging Positive News
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock
Avadel Pharmaceuticals Presents Results From Social Listening Analysis And Survey Of People With Narcolepsy Uncover Real-Life Challenges With Twice-Nightly Oxybate Therapy; Findings Published In 'Brain Sciences' Showed Missed Doses And Potential For...
Avadel Chief Commercial Officer Resigns, Stock Down 14%
UBS Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $22